CRISPR and Cancer

The FDA recently placed a temporary hold on a clinical trial with TALEN gene-edited CAR T-cells. A patient enrolled in this trial developed...

This week’s clinical update focuses on a newly posted Phase 1 clinical trial for a CRISPR-edited CAR-T therapy for relapsed or refractory CD19+...

In this week’s clinical update, we take a look at a CRISPR-engineered T cell receptor-T cell therapy that is designed to treat all genetic subtypes of...

This week’s update looks at P-BCMA-ALLO1, a Cas-CLOVER-edited allogeneic CAR-T candidate that is being developed for the treatment of multiple...

Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...

In a recent landmark paper, Dr Bo Wang and his colleagues at Kyoto University used CRISPR to generate triple-knockout, hypoimmunogenic T cells from...

This week’s clinical update looks at a Phase 1/2 trial for a CRISPR-edited checkpoint cell therapy for difficult-to-treat gastrointestinal cancers...

This week’s clinical update looks at a Phase 1/2 trial for VOR33, a CRISPR-Cas9-edited haematopoietic stem and progenitor cell (HSPC) therapy under...